Clinical trial
A Randomized, Multicenter, Open-label, Phase 3 Clinical Trial Evaluating SYS6043 Versus Investigator's Choice Chemotherapy in Participants With Platinum-resistant Advanced Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer.
NCT07708753 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multicenter, Open-label, Phase 3 Clinical Trial Evaluating SYS6043 Versus Investigator's Choice Chemotherapy in Participants With Platinum-resistant Advanced Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer.
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 15, 2026
- Completion date
- December 1, 2030
- Enrollment
- 460 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
platinum-resistant fallopian tube cancer, platinum-resistant ovarian cancer, platinum-resistant primary peritoneal cancer